In terms of private investments, 2020 was the year of the liquid biopsy.
Setting its sights on the screening setting, Exact aims to be a major liquid biopsy player.
The first pan-cancer approval might have gone to Guardant, but Roche’s subsidiary’s blood test appears to be able to find more markers.
Thrive is in some ways ahead of the competition with the first-ever screening trial of a liquid biopsy, but the test’s sensitivity leaves something to be desired.
The first one-shot billion-dollar venture investment round in the medical technology sector has gone to Verily as computing bleeds into medicine.
A new player has entered the liquid biopsy game.